ASH 2024 movers – moments of reckoning for menin and BTK
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
ASH 2024 – Arcellx is happy to share in Car-T
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
ASH 2024 preview – Arcellx disappoints
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
EHA 2024 preview – Novartis doubles up
The conference’s abstract drop features ASC4First in its plenary session.
ASH 2023 – Arcellx still hopes to challenge Carvykti
The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.
Investors brush off Car-T scare
But the FDA’s investigation looks like worse news for autoimmune disease than oncology.
Gilead ups its bet on Arcellx and BCMA
The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.
